724 results about "Enterococcus" patented technology

The invention relates to a new type antibiotic containing an antibody analog, a preparation method and an application method thereof, which belong to the field of biological medicaments. The new type antibiotic containing an antibody analog comprises colicin E1, Ia, Ib, A, B, N or a water pore canal domain thereof and an antibody analog, wherein the antibody analog is formed by connecting the carboxyl terminal of VHCDR1 of immunoglobulin with the amidogen terminal of VHFR2 and connecting the carboxyl terminal of VHFR2 with the amidogen terminal of VLCD; and porin is identified specifically by the immunoglobulin. The sterilization capability of the antibiotic is thousands of times of that of commonly used antibiotics. Because the action mechanism is special, pathogen is difficult to produce medicament resistant property; human normal cells are not harmed in the process of sterilization; and the new type antibiotic containing an antibody analog can be used for preparing medicaments of resisting meningococcus, vancocin enterococcus, methicillin staphylomycin or multi-medicament resistant cyanomycosis.

The present invention provides human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and / or treatment of a condition resulting from Enterococcus.

DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample DNA from (i) any bacterium, (ii) the species Streptococcus agalactiae, Staphylococcus saprophyticus, Enterococcus faecium, Neisseria meningitidis, Listeria monocytogenes and Candida albicans, and (iii) any species of the genera Streptococcus, Staphylococcus, Enterococcus, Neisseria and Candida are disclosed. DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample antibiotic resistance genes selected from the group consisting of blatem, blarob, blashv, blaoxa, blaZ, aadB, aacC1, aacC2, aacC3, aacA4, aac6'-lla, ermA, ermB, ermC, mecA, vanA, vanB, vanC, satA, aac(6')-aph(2''), aad(6'), vat, vga, msrA, sul and int are also disclosed. The above microbial species, genera and resistance genes are all clinically relevant and commonly encountered in a variety of clinical specimens. These DNA-based assays are rapid, accurate and can be used in clinical microbiology laboratories for routine diagnosis. These novel diagnostic tools should be useful to improve the speed and accuracy of diagnosis of microbial infections, thereby allowing more effective treatments. Diagnostic kits for (i) the universal detection and quantification of bacteria, and / or (ii) the detection, identification and quantification of the above-mentioned bacterial and fungal species and / or genera, and / or (iii) the detection, identification and quantification of the above-mentioned antibiotic resistance genes are also claimed.

Disclosed is a composition and method for the treatment and prevention of bad breath, halitosis, gingivitis, and / or periodontitis that contains one or more varieties of probiotic bacteria from the groups Lactobacillus, Bacillus, Escherichia, Enterococcus, Streptococcus, and Bifidobacterium, and / or a species of the yeast genus Saccharomyces. The composition may be in a variety of forms, such as a toothpaste, mouthwash, oral spray, oral cream or gel, chewing gum, candy, lozenges, dissolvable pill or strip, or powder that may be sprinkled directly into the oral cavity.

DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample DNA from (i) any bacterium, (ii) the species Streptococcus agalactiae, Staphylococcus saprophyticus, Enterococcus faecium, Neisseria meningitidis, Listeria monocytogenes and Candida albicans, and (iii) any species of the genera Streptococcus, Staphylococcus, Enterococcus, Neisseria and Candida are disclosed. DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample antibiotic resistance genes selected from the group consisting of blatem, blarob, blashv, blaoxa, blaZ, aadB, aacC1, aacC2, aacC3, aacA4, aac6′-IIa, ermA, ermB, ermC, mecA, vanA, vanB, vanC, satA, aac(6′)-aph(2″), aad(6), vat, vga, msrA, sul and int are also disclosed. The above microbial species, genera and resistance genes are all clinically relevant and commonly encountered in a variety of clinical specimens. These DNA-based assays are rapid, accurate and can be used in clinical microbiology laboratories for routine diagnosis. These novel diagnostic tools should be useful to improve the speed and accuracy of diagnosis of microbial infections, thereby allowing more effective treatments. Diagnostic kits for (i) the universal detection and quantification of bacteria, and / or (ii) the detection, identification and quantification of the above-mentioned bacterial and fungal species and / or genera, and / or (iii) the detection, identification and quantification of the above-mentioned antibiotic resistance genes are also claimed.

The invention discloses a composite microorganism preparation including the active components as follows: at least two of enterococcus faecalis, saccharomyces cerevisiae and bacillus subtilis, and as well as zymosan and corn starch. The preparation is composed of, by weight, 0.1-15 parts of powder of the enterococcus faecalis, 0.1-15 parts of powder of the saccharomyces cerevisiae, 0.1-10 parts of powder of the bacillus subtilis, 0.1 parts of the zymosan and 59.9-74.9 parts of the corn starch. Compared with the prior art, the enterococcus faecalis, saccharomyces cerevisiae and bacillus subtilis are organically combined so that advantages of the bacteria can be achieved completely. The preparation can adapt different hosts and conditions, can partially, even completely replace antibiotics, and can regulate ecologic balance in gastrointestinal tracts, promote growth, increase conversion rate of feeds and enhance immunity. The preparation can improve enteric microorganism environment in animals, inhibit growth of harmful bacteria and promote reproduction of beneficial bacteria, improves animal immunity and enhances disease resistance, supplies nutrients to animals, improves utilization rate of feed and promotes growth of the animals.

The invention discloses an enterococcus faecium and application thereof. An enterococcus faecium strain provided by the invention is enterococcus faecium suppressant 80, and the collection number is CGMCC No.5058. As proved by experiments, the enterococcus faecium suppressant 80 is obtained by separating, identifying and screening; and the enterococcus faecium suppressant 80 has high resistance, high bacterial resistance and probiotic characteristics, and can be taken as an additive for preparing animal feeds; and the animals include but is not limited to various animals such as pigs, cows, sheep, chicken and the like. The feeds have similar functions to antibiotic feeds, but do not have the side effects of the antibiotic feeds.

The present invention provides one kind of feed level microbe additive and its preparation and application. The microbe additive includes mainly probiotics part and nutritious liquid part. The probiotics part contains acidophilic lactobacillus, fecal enterococcin and butynic clostridium; and the nutritious liquid part contains acetic acid, propanoic acid and butyric acid. The feed level microbe additive is taken by chickling in 24 hr after hatching, and this can reduce the use amount of antiseptic medicine obviously, raise daily weight gain, lower the feed / meat ratio and raise economic utility obviously. In addition, it has simple preparation and low cost.

The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.

The invention discloses enterococcus faecium and a preparation method thereof, relates to the field of microorganisms, and particularly relates to the enterococcus faecium and application thereof. A bacterium sample is acquired from the rumen of a slaughtered goat, subjected to directive breeding at the temperature of 32-42 DEG C under an anaerobic and photophobic condition, and separated and purified by use of a repeated divisional agar streak plate method so as to obtain enterococcus faecium L-01. The enterococcus faecium L-01 can be used as an animal microorganism fodder additive, has the effects of effectively inhibiting pathogenic bacterium in animal digestive tract, improving the micro-ecological environment of the digestive tract and enhancing the immunologic function of an animal body, can be used as a substitute product of antibiotics and can be used for effectively solving the existing serious situation.

The invention discloses a deodorant special for livestock and poultry farms and application thereof, wherein the deodorant is composed of the following strains: 106-108 lactobacillus acidophilus per milliliter, 107-109 lactobacillus reuteri per milliliter, 104-106 bacillus polymyxa per milliliter, 106-108 bacillus lentus per milliliter, 106-109 bacillus coagulans per milliliter, 104-106 enterococcus faecalis per milliliter, 107-109 enterococcus faecium per milliliter, 104-107 candida rugosa per milliliter, 104-107 candida valida per milliliter, 104-106 pseudomonas farinofermentans per milliliter, 106-108 rhodopseudomonas palustris per milliliter, 104-106 geotrichum suaveolens per milliliter, 106-108 aspergillus clavatus per milliliter, 106-108 rough spore aspergillus per milliliter and 106-109 streptomyces globisporus per milliliter. According to the invention, excrements in a poultry house and excrements for accumulative fermentation are treated through a spraying manner, so as to effectively reduce the release amount of malodorous gases, and provide a technical support for the effective treatment of malodor in the livestock and poultry farms and the environmental protection. Besides, the deodorant special for livestock and poultry farms can also be sprayed to the livestock and poultry body surfaces, to keep the livestock and poultry body surfaces clean and sanitary, and be conducive to the growth of livestock and poultry.

The invention provides a ternary compound inoculant for a fermentation bed for pigs. The ternary compound inoculant is prepared from a compound inoculant I, a compound inoculant II and a compound inoculant III, wherein the compound inoculant I is a starting inoculant and consists of trichoderma koningii, bacillus licheniformis and bacillus amyloliquefaciens; the compound inoculant II is a maintaining inoculant and consists of azotobacter chroococcum, enterococcus faecalis, bacillus laterosporus, bacillus amyloliquefaciens and bacillus subtilis; the compound inoculant III is a stacking inoculant and consists of aspergillus oryzae, streptomycete, azotobacter chroococcum, trichoderma koningii and bacillus licheniformis. The ternary compound inoculant provided by the invention is an efficient conversion flora system with complementary function and complementary enzyme system; the compound inoculant I is fermented to produce heat before entering; the compound inoculant II is subjected to biological deodorization, bacteria inhibition and waste transformation in cultivation; the compound inoculant III is decayed at high temperature after being discharged; nutrients are preserved in situ. The ternary compound inoculant system is collaboratively progressive, a continuous circulating fermentation process for cultivation of the fermentation bed is achieved, and healthy and clean production of pigs is facilitated.